tiprankstipranks
Trending News
More News >
Bioxytran Inc (BIXT)
OTHER OTC:BIXT
US Market

Bioxytran (BIXT) Price & Analysis

Compare
20 Followers

BIXT Stock Chart & Stats

$0.08
$0.01(17.50%)
At close: 4:00 PM EST
$0.08
$0.01(17.50%)

BIXT FAQ

What was Bioxytran Inc’s price range in the past 12 months?
Bioxytran Inc lowest stock price was $0.04 and its highest was $0.23 in the past 12 months.
    What is Bioxytran Inc’s market cap?
    Bioxytran Inc’s market cap is $7.91M.
      When is Bioxytran Inc’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Bioxytran Inc’s earnings last quarter?
      Currently, no data Available
      Is Bioxytran Inc overvalued?
      According to Wall Street analysts Bioxytran Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Bioxytran Inc pay dividends?
        Bioxytran Inc does not currently pay dividends.
        What is Bioxytran Inc’s EPS estimate?
        Bioxytran Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Bioxytran Inc have?
        Bioxytran Inc has 98,898,384 shares outstanding.
          What happened to Bioxytran Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Bioxytran Inc?
          Currently, no hedge funds are holding shares in BIXT
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Bioxytran Inc

            Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
            Similar Stocks
            Company
            Price & Change
            Follow
            Adial Pharmaceuticals
            IN8bio
            NLS Pharmaceutics
            Sensei Biotherapeutics
            Cardio Diagnostics Holdings

            Ownership Overview

            1.18%98.82%
            ― Other Institutional Investors
            98.82% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks